Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirsevimab in Healthy Preterm and Term Infants in China
NCT05110261Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nirsevimab in respiratory syncytial virus infection (RSV), lower respiratory tract infection (LRTI), sponsored by AstraZeneca. Started Nov 2021; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)lower respiratory tract infection (LRTI)
Beyond the preview
Go deeper on NCT05110261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110261.